✦ LIBER ✦

PRS34 Cost-Effectiveness of Roflumilast (DAXAS®) in the Treatment Of Chronic Obstructive Pulmonary Disease (COPD) in Spain

✍ Scribed by Lindner, L.; Camins de Valdenebro, L.; Aparicio Martinez, J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PRS22 COST-EFFECTIVENESS ANALYSIS OF TIO

✍ M Brosa; S Díaz; M Miravitlles; N Gonzalez-Rojas; D Nieves 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

PRS8 COST-EFFECTIVENESS ANALYSIS OF TIOT

✍ S Nishimura; M Kobayashi; T Hasegawa 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

PRS38 The Cost-Effectiveness of Roflumil

✍ Engström, A. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

PRS6 EVALUATING THE COST-EFFECTIVENESS O

✍ S Naik; KM Kamal; P Keys; T Mattei 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

Cost-Effectiveness Analysis of Glycopyrr

✍ Torres, C.; Betoret, I.; Sabater, E.; Figueras, M.; Casado, M.A. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

The costs of exacerbations in chronic ob

✍ FREDRIK ANDERSSON; SIXTEN BORG; SVEN-ARNE JANSSON; ANN-CHRISTIN JONSSON; ÅSA ERI 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 206 KB